Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
Laurent Poirel, Mustafa Sadek, Ayda Kusaksizoglu, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2022) Vol. 41, Iss. 4, pp. 677-680
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis
Antibiotics (2022) Vol. 11, Iss. 6, pp. 723-723
Open Access | Times Cited: 147
Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options
Theodoros Karampatakis, Katerina Tsergouli, Payam Behzadi
Antibiotics (2023) Vol. 12, Iss. 2, pp. 234-234
Open Access | Times Cited: 141
Klebsiella pneumoniae carbapenemase variants: the new threat to global public health
Li Ding, Siquan Shen, Jing Chen, et al.
Clinical Microbiology Reviews (2023) Vol. 36, Iss. 4
Open Access | Times Cited: 65
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa
Laurent Poirel, José Manuel Ortiz de la Rosa, Mustafa Sadek, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 4
Open Access | Times Cited: 61
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections
Ursula Theuretzbacher, Benjamin Blasco, Maëlle Duffey, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 957-975
Closed Access | Times Cited: 39
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
Keith S. Kaye, Thierry Naas, Jason M. Pogue, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 3, pp. 777-806
Open Access | Times Cited: 35
Multidrug-resistant Gram-negative bacterial infections
Nenad Macesic, Anne‐Catrin Uhlemann, Anton Y. Peleg
The Lancet (2025) Vol. 405, Iss. 10474, pp. 257-272
Closed Access | Times Cited: 1
Evolution of β-lactamase-mediated cefiderocol resistance
Christopher Frøhlich, Vidar Sørum, Nobuhiko Tokuriki, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 77, Iss. 9, pp. 2429-2436
Open Access | Times Cited: 34
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam
J. Nicholas O’Donnell, Thomas P. Lodise
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 7
Open Access | Times Cited: 31
Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
Gabriele Bianco, Matteo Boattini, Sara Comini, et al.
Antibiotics (2023) Vol. 12, Iss. 3, pp. 604-604
Open Access | Times Cited: 19
Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy
Matteo Boattini, Gabriele Bianco, Lorena Charrier, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2023) Vol. 42, Iss. 4, pp. 431-439
Closed Access | Times Cited: 16
An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
Sara Domingues, Tiago Lima, María José Saavedra, et al.
Life (2023) Vol. 13, Iss. 7, pp. 1427-1427
Open Access | Times Cited: 16
Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it’s even arrived?
Chiara Russo, Alessio Mesini, Marcello Mariani, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 4, pp. 624-631
Open Access | Times Cited: 5
Carbapenem-resistant Gram-negative bacteria (CR-GNB) in ICUs: resistance genes, therapeutics, and prevention – a comprehensive review
Qi Li, Xiaoshi Zhou, Rou Yang, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 5
Evolution of ceftazidime/avibactam resistance and plasmid dynamics in OXA-48-producing Klebsiella spp. during long-term patient colonization
Salud Rodríguez-Pallares, María Alejandra Mateo-Vargas, Manuel Rodríguez‐Iglesias, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Closed Access
In the Literature

Clinical Infectious Diseases (2025) Vol. 80, Iss. 3, pp. i-iii
Closed Access
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms
Sena Nur Başaran, Lütfiye Öksüz
Archives of Microbiology (2025) Vol. 207, Iss. 5
Closed Access
Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update
Ana Allende, Avelino Álvarez‐Ordóñez, Valeria Bortolaia, et al.
EFSA Journal (2025) Vol. 23, Iss. 4
Open Access
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1
Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez, Juan Carlos Vázquez-Ucha, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 5
Open Access | Times Cited: 12
The mechanism of ceftazidime and cefiderocol hydrolysis by D179Y variants of KPC carbapenemases is similar and involves the formation of a long-lived covalent intermediate
André Birgy, Christina Nnabuife, Timothy Palzkill
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 3
Open Access | Times Cited: 4
In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol
Richard Kriz, Kathrin Spettel, Alina Pichler, et al.
The Journal of Antibiotics (2024) Vol. 77, Iss. 11, pp. 757-767
Open Access | Times Cited: 4
Challenges and shortcomings of antibacterial discovery projects
Ursula Theuretzbacher, Enrico Baraldi, Francesco Ciabuschi, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 5, pp. 610-615
Open Access | Times Cited: 18
Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Enterobacterales
Mustafa Sadek, Juan Bosch Duran, Laurent Poirel, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 5
Open Access | Times Cited: 9
Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022)
Matteo Boattini, Gabriele Bianco, Paulo Bastos, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2023) Vol. 43, Iss. 1, pp. 155-166
Open Access | Times Cited: 9
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol
Gabriele Bianco, Matteo Boattini, Monica Cricca, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 12, pp. 14132-14153
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top